Free Trial

Predictive Oncology Q2 2024 Earnings Report

Predictive Oncology logo
$0.69 -0.03 (-3.82%)
(As of 12/20/2024 05:45 PM ET)

Predictive Oncology EPS Results

Actual EPS
-$0.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Predictive Oncology Revenue Results

Actual Revenue
$0.28 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Predictive Oncology Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Predictive Oncology Earnings Headlines

The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Predictive Oncology downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgrades Predictive Oncology (POAI) to a Hold
See More Predictive Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Predictive Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Predictive Oncology and other key companies, straight to your email.

About Predictive Oncology

Predictive Oncology (NASDAQ:POAI) operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

View Predictive Oncology Profile

More Earnings Resources from MarketBeat

Upcoming Earnings